Bruker Corporation (BRKR)
NASDAQ: BRKR · Real-Time Price · USD
33.75
-1.30 (-3.71%)
At close: Mar 13, 2026, 4:00 PM EDT
33.76
+0.01 (0.03%)
After-hours: Mar 13, 2026, 7:42 PM EDT
Bruker Revenue
In the year 2025, Bruker had annual revenue of $3.44B with 2.08% growth. Bruker had revenue of $977.20M in the quarter ending December 31, 2025, a decrease of -0.24%.
Revenue (ttm)
$3.44B
Revenue Growth
+2.08%
P/S Ratio
1.49
Revenue / Employee
$310,014
Employees
11,085
Market Cap
5.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.44B | 70.10M | 2.08% |
| Dec 31, 2024 | 3.37B | 401.90M | 13.56% |
| Dec 31, 2023 | 2.96B | 433.80M | 17.14% |
| Dec 31, 2022 | 2.53B | 112.80M | 4.67% |
| Dec 31, 2021 | 2.42B | 430.40M | 21.66% |
| Dec 31, 2020 | 1.99B | -85.10M | -4.11% |
| Dec 31, 2019 | 2.07B | 177.00M | 9.34% |
| Dec 31, 2018 | 1.90B | 129.70M | 7.34% |
| Dec 31, 2017 | 1.77B | 154.60M | 9.59% |
| Dec 31, 2016 | 1.61B | -12.50M | -0.77% |
| Dec 31, 2015 | 1.62B | -185.10M | -10.23% |
| Dec 31, 2014 | 1.81B | -30.50M | -1.66% |
| Dec 31, 2013 | 1.84B | 48.00M | 2.68% |
| Dec 31, 2012 | 1.79B | 139.70M | 8.46% |
| Dec 31, 2011 | 1.65B | 346.80M | 26.58% |
| Dec 31, 2010 | 1.30B | 190.40M | 17.08% |
| Dec 31, 2009 | 1.11B | 7.40M | 0.67% |
| Dec 31, 2008 | 1.11B | 74.70M | 7.24% |
| Dec 31, 2007 | 1.03B | 181.00M | 21.26% |
| Dec 31, 2006 | 851.40M | 479.15M | 128.72% |
| Dec 31, 2005 | 372.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Globus Medical | 2.94B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Integer Holdings | 1.85B |
| Masimo | 1.53B |
| Penumbra | 1.40B |
| LivaNova | 1.39B |
| Haemonetics | 1.32B |
BRKR News
- 18 days ago - Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR - Business Wire
- 19 days ago - Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications - Business Wire
- 20 days ago - Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum - Business Wire
- 20 days ago - Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology - Business Wire
- 4 weeks ago - These Analysts Cut Their Forecasts On Bruker Following Q4 Results - Benzinga
- 4 weeks ago - Bruker Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Business Wire
- 4 weeks ago - Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration - Business Wire